You are here:  Home  >  Banking & Finance  >  Current Article

Amgen inks $180M nanomedicine deal

By   /   Tuesday, January 8th, 2013  /   Comments Off

    Print       Email

Thousand Oaks-based Amgen has entered a deal to pay up to $180.5 million for nanomedicine tumor treatments being developed by a Massachusetts company.

Cambridge-based Bind Biosciences said it has entered a development agreement with Amgen for its kinase inhibitor nanomedicines for treating a range of solid tumors. The medicines are highly targeted and can be programmed to seek certain kinds of cells, the firm said in a release.

Under the agreement, Amgen will have the right to develop and commercialize the drug for the treatment of whatever tumor types Amgen selects. In exchange, Bind could receive up-front and development milestone payments totaling $46.5 million up to an additional $134 million in regulatory and sales milestone payments for the first therapeutic use. The Massachusetts company also said it will receive tiered royalties on potential future sales.

    Print       Email
  • Sign up for email news

    Get the Business Times in your inbox. Sign up for breaking news alerts, our weekly briefing, and more.
    Sign up
  • The Latest Lists

    The Latest Lists

    Purchase the digital version of the 2014 Book of Lists or download Excel versions of our weekly Top 25 lists. [Click here]

  • 2013 Giving Guide

    2013 Giving Guide

    Read our free guide to nonprofits and philanthropy in the Tri-Counties

You might also like...

SBAM parent to sell to TIAA-CREF

Read More →